{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:48:53Z","timestamp":1758815333202,"version":"3.37.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Dr Albayda has been funded by the Jerome L Greene Foundation and Cupid Foundation"},{"name":"L Kirschstein National Research Service Award Institutional Research","award":["T32"],"award-info":[{"award-number":["T32"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Dermatomyositis (DM) and alopecia areata are two diseases characterised by aberrant interferon signalling. While patchy alopecia of the scalp is a known feature of DM, alopecia universalis, which involves hair loss over the entire body, has rarely been reported in conjunction with DM. Herein, we report the case of a 30-year-old female with DM who developed refractory cutaneous disease and alopecia universalis that were successfully treated with tofacitinib. This could suggest that concomitant severe alopecia and refractory cutaneous DM may reflect a strong baseline interferon gene signature that may predict responsiveness to janus kinase inhibitors.<\/jats:p>","DOI":"10.1093\/mrcr\/rxac012","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:53:00Z","timestamp":1646650380000},"page":"199-202","source":"Crossref","is-referenced-by-count":4,"title":["Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-9420","authenticated-orcid":false,"given":"Rochelle","family":"Castillo","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine , New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-9504","authenticated-orcid":false,"given":"Jemima","family":"Albayda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine , Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"2022062410420569400_R1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2022062410420569400_R2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"2022062410420569400_R3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","article-title":"Type 1 interferon signature in the scalp lesions of alopecia areata","volume":"163","author":"Ghoreishi","year":"2010","journal-title":"Br J Dermatol"},{"key":"2022062410420569400_R4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"key":"2022062410420569400_R5","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139558","article-title":"IL-18-containing five-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions","volume":"5","author":"Tsoi","year":"2020","journal-title":"JCI Insight"},{"key":"2022062410420569400_R6","first-page":"33","article-title":"Interferon-gamma in alopecia areata","volume":"14","author":"Arca","year":"2004","journal-title":"Eur J Dermatol"},{"key":"2022062410420569400_R7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archderm.139.12.1555","article-title":"Histopathologic features of alopecia areata: a new look","volume":"139","author":"Whiting","year":"2003","journal-title":"Arch Dermatol"},{"key":"2022062410420569400_R8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/DAD.0b013e31818520e1","article-title":"Dermatomyositis: a clinicopathological study of 40 patients","volume":"31","author":"Smith","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"2022062410420569400_R9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022062410420569400_R10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"2022062410420569400_R11","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022062410420569400_R12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"2022062410420569400_R13","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13718","article-title":"Interferon-gamma serum level and immunohistochemical expression of CD8 cells in tissue biopsies in patients with alopecia areata in correlation with trichoscopic findings","volume":"33","author":"Agamia","year":"2020","journal-title":"Dermatol Ther"},{"key":"2022062410420569400_R14","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis from the National Institute of Arthritis and musculoskeletal and skin diseases","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2022062410420569400_R15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000464469","article-title":"Clinical and dermoscopic features of the scalp in 31 patients with dermatomyositis","volume":"3","author":"Jasso-Olivares","year":"2017","journal-title":"Ski Appendage Disord"},{"key":"2022062410420569400_R16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3481","article-title":"Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib","volume":"100","author":"Fetter","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2022062410420569400_R17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.41627","article-title":"Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis\u2013related interstitial lung disease","volume":"73","author":"Assassi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022062410420569400_R18","doi-asserted-by":"crossref","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a validated interferon score using nanostring technology","volume":"38","author":"Kim","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"2022062410420569400_R19","first-page":"1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci Rep"},{"key":"2022062410420569400_R20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1496401","article-title":"Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor","volume":"257","author":"Schindler","year":"1992","journal-title":"Science"},{"key":"2022062410420569400_R21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri3044","article-title":"NK cell development, homeostasis and function: parallels with CD8+ T cells","volume":"11","author":"JC","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2022062410420569400_R22","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2018.00271","article-title":"The role of CXCR3 and its chemokine ligands in skin disease and cancer","volume":"5","author":"Zeng","year":"2018","journal-title":"Front Med"},{"key":"2022062410420569400_R23","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/849573","article-title":"Epigenetic control of interferon-gamma expression in CD8 T cells","volume":"2015","author":"Ara\u00fajo-Souza","year":"2015","journal-title":"J Immunol Res"},{"key":"2022062410420569400_R24","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2022062410420569400_R25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022062410420569400_R26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410420569400_R27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"2022062410420569400_R28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2022062410420569400_R29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxac012\/43057428\/rxac012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/199\/44245260\/rxac012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/199\/44245260\/rxac012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:43:01Z","timestamp":1656067381000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/2\/199\/6543355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,7]]},"published-print":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxac012","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,7]]}}}